MT-0169 is an investigative therapy that contains an antibody fragment targeting CD38 (a protein found in high levels on the surface of myeloma cells. It is fused to a Shiga-like toxin A-subunit (SLTA), a bacterial protein that, once inside malignant myeloma cells, irreversibly blocks the protein-making machinery of the cell and kills it.

SparkCures ID 352
Developed By Molecular Templates
Generic Name MT-0169
Treatment Classifications
  • Engineered Toxin Body (EBT)
Treatment Targets

Clinical Trials